List view / Grid view
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This research group is seeking the potential to unravel novel methods to remove bacterial biofilms from oral surfaces. Oral biofilms consist of a large variety of microorganisms embedded in a complex and robust extracellular matrix...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers sprayed a dye on oesophageal tissue samples taken from people with Barrett’s oesophagus – a condition that risk cancer development...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The loss of CHD1, one of the most mutated genes in prostate tumours, sensitises human prostate cancer cells to different drugs, a biomarker for...
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The blood test detects mutations to a gene called oestrogen receptor 1, or ESR1, which indicate that receptors for the female hormone oestrogen in the cancer cells, which are usually driven by the hormone, have evolved to stay permanently switched on without it – meaning hormonal treatments that block oestrogen…
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A collaboration to investigate the link between epigenetics and respiratory disease and to find new drug treatments involves...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Takeda’s global non-interventional, observational multiple myeloma study is now enrolling patients, aiming to have 5,000 patients over three years with a goal of following each patient for a minimum of five years in an effort to track patterns in disease presentation, patient characteristics, treatment and outcomes, thereby enhancing the understanding…
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CRISPR/Cas9 is likely one of the most revolutionary tools in biotechnology, with tremendous implications for a broad range of biological and medical disciplines. As programmable scissors this technology allows cleavage of DNA at predefined sites in the genome of cells...
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Using advanced stem cell technology, scientists from the Icahn School of Medicine at Mount Sinai have created a model of a heart condition called hypertrophic cardiomyopathy (HCM), an excessive thickening of the heart that is associated with a number of rare and common illnesses, some of which have a strong…
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Using a mouse model, the rate of miscarriage was over 20% in the group that was not transplanted with EPCs while the miscarriage rate was only 5% in...
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The scientists were able to prove that the β2 subunit of the nicotinic receptor is the direct target of soluble amyloid beta peptide...
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Used for the first time as part of the team's latest work, the model may become a valuable experimental tool to analyse metastatic potential in sarcomas...
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
A research group has identified an enzyme, PRDM2, whose production is turned off in nerve cells of the frontal lobe when alcohol dependence develops...
26 August 2016 | By Niamh Louise Marriott, Digital Content Producer
At the onset of puberty, the emergence of a novel inhibitory brain receptor, α4βδ (alpha four beta delta), reduces epilepsy seizure-like activity in mouse...
26 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The integral nature of the mice model market with the pharmaceutical and biomedical fields has allowed companies from these industries to form alliances...
